SCHEMBL25754652

SCHEMBL25754652

CC#CCCCNCCN1CCCCC1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.42
PRMT6 Q96LA8 1/20 0.42
PRMT8 Q9NR22 1/20 0.42
ACE2 Q9BYF1 1/20 0.41
KDM1A O60341 1/20 0.40
SIGMAR1 Q99720 3/20 0.39
HRH3 Q9Y5N1 1/20 0.38
SCN5A Q14524 2/20 0.37
DPP7 Q9UHL4 1/20 0.37
MAPT P10636 2/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA2 P00918 2/20 0.35
CA9 Q16790 2/20 0.35
NPC1 O15118 1/20 0.34
ALDH1A1 P00352 1/20 0.34
KDM4E B2RXH2 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25754655 0.92 HRH3 (0.45) CARM1PRMT6PRMT8KDM1ASIGMAR1
SCHEMBL25754680 0.88 CARM1 (0.36) CARM1PRMT6PRMT8ACE2KDM1A
SCHEMBL25754653 0.85 HRH3 (0.45) CARM1PRMT6PRMT8KDM1ASIGMAR1
SCHEMBL25754677 0.85 HRH3 (0.38) CARM1PRMT6PRMT8SIGMAR1HRH3
SCHEMBL25754665 0.85 CARM1 (0.36) CARM1PRMT6PRMT8ACE2KDM1A
SCHEMBL25754685 0.84 HRH3 (0.40) SIGMAR1HRH3SCN5A
SCHEMBL25754658 0.81 CARM1 (0.38) CARM1PRMT6PRMT8ACE2KDM1A
SCHEMBL6051858 0.79 ACE2 (0.56) CARM1PRMT6PRMT8ACE2KDM1A
SCHEMBL25754671 0.79 HRH3 (0.38) CARM1PRMT6PRMT8SIGMAR1HRH3
SCHEMBL25754570 0.78 HRH3 (0.60) SIGMAR1HRH3MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) 2023-07-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230210999-A1 TARGETED PROTEASE DEGRADATION (TED) PLATFORM UCHL3, UBE2L3, ADAM33 CARM1 1753/4885PRMT6 1350/4885PRMT8 1536/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.